FDA Approves Bayer’s Over the Counter Nasal Allergy Spray
The FDA removed the prescription requirement for Bayer’s Asteprofor seasonal and year-round allergic rhinitis nasal spray.
Tag: Bayer
All
Latest
FDA Approves Bayer’s Over the Counter Nasal Allergy Spray
The FDA removed the prescription requirement for Bayer’s Asteprofor seasonal and year-round allergic rhinitis nasal spray.
Read More
FDA Approves Astepro Antihistamine for OTC Use
The FDA approved Bayer’s Astepro (azelastine hydrochloride nasal spray, 0.15%) for nonprescription use agaiseasonal and perennial allergic rhinitis
Read MoreBayer Enrolling Patients in Phase 4 PAH Trial of Riociguat
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH).
Read More
Bayer to Present Data on PAH Drugs at ATS 2017
Bayer will present clinical data from on riociguat (Adempas), which is approved to treat pulmonary arterial hypertension (PAH), at ATS 2017 in Washington DC.
Read More
EMA Halts Use of Riociguat for PH Associated Idiopathic Interstitial Pneumonia
The European Medicines Agency has advised that Adempas (riociguat) should not be prescribed to patients with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia.
Read More
Riociguat Safe, Effective for Treating CTEPH Long-term
The results from an ongoing Phase 3 study supports the long-term use of riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Read More
Bayer Terminates Phase II Study of Riociguat for PH-associated Idiopathic Interstitial Pneumonias
Bayer Pharmaceuticals is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias.
Read MoreBayer’s Investigational Drug Shows Promise in PAH Treatment, Phase III Study Finds
The drug, ricoiguat, could prove effective as a treatment option for patients with PAH.
Read More